Literature DB >> 35866899

The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics

Imke Nordhorn1, Daniela Weiss2, Thomas Werfel1,3, Alexander Zink2, Maximilian C Schielein2, Stephan Traidl1,3.   

Abstract

Background: The COVID-19 pandemic has led to widespread changes in medical care. However, it is still unclear to what extent the care of patients suffering from moderate-to-severe psoriasis, chronic spontaneous urticaria or atopic dermatitis has been affected.
Objectives: This study was conducted to determine the impact of the SARS-CoV-2 pandemic on medical care in dermatological practices, focusing on physicians’ concerns related to susceptibility to infections in combination with different treatment modalities. Materials &
Methods: Dermatologists working in medical offices in the German federal states of Bavaria and Lower Saxony participated in a cross-sectional, non-interventional, questionnaire-based study investigating the influence of COVID-19 on dermatological care. The study was performed after the first wave of the coronavirus pandemic in July/August, 2020.
Results: A total of 195 dermatologists participated in the study. Almost one in five practices were closed for at least one week during the pandemic. The care of patients with chronic inflammatory skin diseases was impaired, affecting diagnostic investigation. Physicians stated that the pandemic substantially influenced systemic therapy. Nearly half of physicians surveyed were concerned about increased susceptibility to infections under biological therapy. No significant differences were identified between the German federal states of Bavaria and Lower Saxony in the south and north of Germany, respectively.
Conclusion: This study reveals a significant impact of the COVID-19 pandemic on the care of dermatological patients in medical offices in Germany. New management modalities and continuous education are needed to improve care in pandemic situations.

Entities:  

Keywords:  COVID-19; chronic inflammatory skin diseases; biologics

Mesh:

Substances:

Year:  2022        PMID: 35866899      PMCID: PMC9463962          DOI: 10.1684/ejd.2022.4222

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   2.805


  45 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors:  Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal:  N Engl J Med       Date:  2013-02-24       Impact factor: 91.245

Review 3.  COVID-19 and implications for dermatological and allergological diseases.

Authors:  Timo Buhl; Stefan Beissert; Evelyn Gaffal; Matthias Goebeler; Michael Hertl; Cornelia Mauch; Kristian Reich; Enno Schmidt; Michael P Schön; Michael Sticherling; Cord Sunderkötter; Claudia Traidl-Hoffmann; Thomas Werfel; Dagmar Wilsman-Theis; Margitta Worm
Journal:  J Dtsch Dermatol Ges       Date:  2020-07-27       Impact factor: 5.584

4.  S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment.

Authors:  Alexander Nast; Lasse Amelunxen; Matthias Augustin; Wolf-Henning Boehncke; Corinna Dressler; Matthew Gaskins; Peter Härle; Bernd Hoffstadt; Joachim Klaus; Joachim Koza; Ulrich Mrowietz; Hans-Michael Ockenfels; Sandra Philipp; Kristian Reich; Thomas Rosenbach; Berthold Rzany; Martin Schlaeger; Gerhard Schmid-Ott; Michael Sebastian; Ralph von Kiedrowski; Tobias Weberschock
Journal:  J Dtsch Dermatol Ges       Date:  2018-05       Impact factor: 5.584

5.  Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries.

Authors:  Alexander G S Zink; Bernd Arents; Antje Fink-Wagner; Irmtraud A Seitz; Ute Mensing; Niels Wettemann; Giuseppe de Carlo; Johannes Ring
Journal:  Acta Derm Venereol       Date:  2019-03-01       Impact factor: 4.437

6.  A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.

Authors:  Katie Bechman; Sujith Subesinghe; Sam Norton; Fabiola Atzeni; Massimo Galli; Andrew P Cope; Kevin L Winthrop; James B Galloway
Journal:  Rheumatology (Oxford)       Date:  2019-10-01       Impact factor: 7.580

7.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Authors:  Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu
Journal:  N Engl J Med       Date:  2016-09-30       Impact factor: 91.245

Review 8.  Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review.

Authors:  T Zuberbier; J Lötvall; S Simoens; S V Subramanian; M K Church
Journal:  Allergy       Date:  2014-08-01       Impact factor: 13.146

9.  The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.

Authors:  T Zuberbier; W Aberer; R Asero; A H Abdul Latiff; D Baker; B Ballmer-Weber; J A Bernstein; C Bindslev-Jensen; Z Brzoza; R Buense Bedrikow; G W Canonica; M K Church; T Craig; I V Danilycheva; C Dressler; L F Ensina; A Giménez-Arnau; K Godse; M Gonçalo; C Grattan; J Hebert; M Hide; A Kaplan; A Kapp; C H Katelaris; E Kocatürk; K Kulthanan; D Larenas-Linnemann; T A Leslie; M Magerl; P Mathelier-Fusade; R Y Meshkova; M Metz; A Nast; E Nettis; H Oude-Elberink; S Rosumeck; S S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; P Staubach; G Sussman; E Toubi; G A Vena; C Vestergaard; B Wedi; R N Werner; Z Zhao; M Maurer
Journal:  Allergy       Date:  2018-07       Impact factor: 13.146

10.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Authors:  Alan Menter; Stephen K Tyring; Kenneth Gordon; Alexa B Kimball; Craig L Leonardi; Richard G Langley; Bruce E Strober; Martin Kaul; Yihua Gu; Martin Okun; Kim Papp
Journal:  J Am Acad Dermatol       Date:  2007-10-23       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.